Iovance Biotherapeutics, Inc. IOVA
Analyst Consensus
Price Objectif
Analyst historical
| Analyste | Entreprise | Prix lors de l'analyse | Prix cible | Gain potentiel | Date de publication |
|---|---|---|---|---|---|
| David Dai | UBS | 1.66 $ | 2 $ | 0.34 % | 16/05/2025 |
| Joseph Catanzaro | Piper Sandler | 5.85 $ | 7.5 $ | 1.65 % | 31/01/2025 |
| David Dai | UBS | 9.82 $ | 17 $ | 7.18 % | 24/10/2024 |
| Benjamin Burnett | Stifel Nicolaus | 3.97 $ | 23 $ | 19.03 % | 09/08/2024 |
| Colleen Kusy | Robert W. Baird | 3.97 $ | 24 $ | 20.03 % | 09/08/2024 |
| Joseph Catanzaro | Piper Sandler | 9.25 $ | 10 $ | 0.75 % | 29/07/2024 |
| Reni Benjamin | JMP Securities | 4 $ | 23 $ | 19.00 % | 20/06/2024 |
| Benjamin Burnett | Stifel Nicolaus | 4.44 $ | 28 $ | 23.56 % | 31/05/2024 |
| Joseph Catanzaro | Piper Sandler | 14.21 $ | 19 $ | 4.79 % | 14/03/2024 |
| Madhu Kumar | Goldman Sachs | 7.17 $ | 6 $ | -1.17 % | 08/12/2022 |
| Joseph Catanzaro | Piper Sandler | 6.62 $ | 11 $ | 4.38 % | 20/11/2022 |
| Michael Ulz | Robert W. Baird | 5.75 $ | 25 $ | 19.25 % | 23/08/2022 |
| Colleen Kusy | Robert W. Baird | 18.23 $ | 34 $ | 15.77 % | 07/04/2022 |
| Colleen M. Kusy | Robert W. Baird | 16.56 $ | 30 $ | 13.44 % | 05/04/2022 |
| Benjamin Burnett | Stifel Nicolaus | 15.04 $ | 25 $ | 9.96 % | 28/01/2022 |
| Nick Abbott | Wells Fargo | 16.82 $ | 25 $ | 8.18 % | 05/01/2022 |
| Peter Lawson | Barclays | 16.33 $ | 40 $ | 23.67 % | 19/05/2021 |